AbbVie has announced a new USD 60 million investment at its production and processing facility in Campoverde Di Aprilia in Lazio. The investment is seen as part of a wider strategy to meet expected increases in future demand for HCV medicines and to ensure an adequate API supply. The production site is expected to become operational by the end of 2017.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
168.8 USD | +0.46% |
|
+0.38% | +8.85% |
12/07 | AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis | MT |
12/07 | AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.85% | 30TCr | |
+62.87% | 86TCr | |
+38.95% | 63TCr | |
-3.99% | 36TCr | |
+16.20% | 32TCr | |
+5.89% | 23TCr | |
+16.53% | 23TCr | |
+15.51% | 18TCr | |
+1.77% | 16TCr | |
+2.41% | 13TCr |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Plans to Invest USD 60 Million in Innovative Production Facility in Italy